Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 64Breast 32Genitourinary 19Thoracic 15CNS 11Sarcoma 10Gynecologic 10Head & Neck 9Other solid neoplasm 3Tumor-Agnostic 2Other hematologic neoplasm 2Plasma cell 1Lymphoid 1Dermatologic 1

Conditions

Uveal Melanoma 1Neoplasm Metastasis 1Melanoma 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoadjuvant Therapy × Dermatologic × Clear all
NCT00324727 2021-06-21

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Delcath Systems Inc.

Phase 3 Completed
93 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡